Table 2.
Altered Genes and Proportion of Cell-Free DNA (n=31 patients with detectable alterations)
| Gene | Alterations, n (%1) | Median % cfDNA (range) | ||
|---|---|---|---|---|
| All Cancers (n=31) | Appendiceal Cancer (n=21) | Colon Cancer (n=7) | ||
| TP53 | 16 (25.8) | 12 (32.4) | 3 (15.0) | 0.40 (0.10–4.00) |
| KRAS | 7 (11.3) | 3 (8.1) | 4 (20.0) | 0.52 (0.20–1.65) |
| EGFR | 4 (6.5) | 3 (8.1) | 1 (5.0) | 0.13 (0.10–0.30) |
| NF1 | 4 (6.5) | 4 (10.8) | 0.65 (0.40–4.10) | |
| TERT | 4 (6.5) | 3 (8.1) | 1 (5.0) | 4.46 (0.30–10.10) |
| APC | 3 (4.8) | 1 (2.7) | 1 (5.0) | 0.10 (0.10–0.40) |
| GNAS | 3 (4.8) | 1 (2.7) | 1 (5.0) | 0.20 (0.20–3.60) |
| ARID1A | 2 (3.2) | 1 (2.7) | 1 (5.0) | 0.80 (0.20–1.40) |
| ATM | 2 (3.2) | 1 (2.7) | 1 (5.0) | 0.80 (0.30–1.30) |
| MET | 2 (3.2) | 1 (5.0) | 0.40 (0.20–0.60) | |
| PIK3CA | 2 (3.2) | 1 (2.7) | 1 (5.0) | 0.75 (0.10–1.40) |
| ARAF | 1 (1.6) | 1 (2.7) | 0.3 | |
| CCND1 | 1 (1.6) | 1 (2.7) | Amplification | |
| CCND2 | 1 (1.6) | 1 (5.0) | Amplification | |
| ERBB2 | 1 (1.6) | 1 (2.7) | 0.2 | |
| FGFR2 | 1 (1.6) | 1 (2.7) | 0.2 | |
| HNF1A | 1 (1.6) | 0.3 | ||
| JAK2 | 1 (1.6) | 1 (2.7) | 1.8 | |
| MYC | 1 (1.6) | 1 (5.0) | Amplification | |
| NOTCH | 1 (1.6) | 1 (5.0) | 1.42 | |
| PDGFRA | 1 (1.6) | 1 (2.7) | 0.4 | |
| RAF1 | 1 (1.6) | 1 (2.7) | 0.1 | |
| RIT1 | 1 (1.6) | 1 (5.0) | 0.1 | |
| SMAD4 | 1 (1.6) | 1 (5.0) | 0.2 | |
| Total Alterations | 62 | 37 | 20 | 0.30 (0.10–10.10) |
| Median Number Alterations/Patient (range) | 1 (1–9) | 1 (1–9) | 2 (1–6) | |
| Total Number Distinct Alterations | 59 | 36 | 19 | |
| Total Number Distinct Genes Altered | 24 | 17 | 15 | |
1
% of total alterations in designated cancer types; alterations include characterized alterations and VUS